PubMed
ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves neuropathic symptoms in patients with sarcoidosis
Dahan A, Dunne A, Swartjes M, et al. Mol Med. 2013
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 33% · Mixed 67% · Unfavorable overall 0%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 2+ mg · Most common: 2+ mg
Reports span 2 to ≥ 2 mg (open-ended top bucket)
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 14% · Mixed 0% · Unfavorable overall 86%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 5+ mg · Most common: 5+ mg
Reports span 0.4 to ≥ 5 mg (open-ended top bucket)
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Published sources linked on the ARA-290 and Tirzepatide wiki pages.
PubMed
Dahan A, Dunne A, Swartjes M, et al. Mol Med. 2013
PubMed
van Velzen M, Heij L, Niesters M, et al. Expert opinion on investigational drugs. 2014
PubMed
Rendell MS. Expert opinion on investigational drugs. 2021
FDA Drug Label
Eli Lilly. FDA Drug Label. 2022
PubMed
Jastreboff AM, Aronne LJ, Ahmad NN, et al. N Engl J Med. 2022
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Frías JP, Davies MJ, Rosenstock J, et al. N Engl J Med. 2021
PubMed
Frias JP, De Block C, Brown K, et al. J Clin Endocrinol Metab. 2024
FDA Drug Label
Eli Lilly. FDA Drug Label. 2023
PubMed
Garvey WT, Frias JP, Jastreboff AM, et al. Lancet (London, England). 2023
PubMed
Jastreboff AM, le Roux CW, Stefanski A, et al. The New England journal of medicine. 2025
PubMed
Ceriello A, Prattichizzo F, Lucisano G, et al. Lancet Reg Health Eur. 2026
PubMed
Aronne LJ, Ahmad NN, Fletcher M, et al. JAMA. 2024